Iovance Biotherapeutics (NASDAQ: IOVA)
Iovance Biotherapeutics Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Iovance Biotherapeutics Company Info
Iovance Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of cell therapies as novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors. The company was founded by Robert T. Brooke on September 17, 2007, and is headquartered in San Carlos, CA.
News & Analysis
Better Growth Biotech Buy: Iovance Biotherapeutics vs CRISPR Therapeutics
These companies are in the early days of their growth stories.
Forget Eli Lilly. Buy This Magnificent Biotech Stock Instead
This company's growth story is about to get moving with gusto.
1 Wall Street Analyst Thinks Iovance Biotherapeutics Stock Is Going to $32. Is It a Buy Around $17?
Its revenue is set to grow, and one of its trials is no longer paused.
Iovance Biotherapeutics Stock Has 22% Upside, According to 1 Wall Street Analyst
With its first approval in hand, attention is now on the top line.
Could Iovance Biotherapeutics Stock Help You Become a Millionaire?
Does Iovance Biotherapeutics stock possess enough upside to generate life-changing returns for your portfolio?
Why Iovance Biotherapeutics Stock Got Trounced on Thursday
A robust rally ended abruptly with the publication of the company's latest fundamentals.
Iovance Therapeutics Stock Has Skyrocketed Over 100% so Far This Year. Is It Still a Buy?
More gains might be on the way for this high-flying biotech stock.
1 Soaring Growth Stock That Could Rise Another 53%, According to Wall Street
A successful launch of its first approved therapy could push shares of this innovative new cancer drug developer through the roof.
Valuation
Earnings Transcripts
Iovance Biotherapeutics, inc (IOVA) Q3 2021 Earnings Call Transcript
IOVA earnings call for the period ending September 30, 2021.
Iovance Biotherapeutics, Inc. (IOVA) Q1 2020 Earnings Call Transcript
IOVA earnings call for the period ending March 31, 2020.
Iovance Biotherapeutics, Inc. (IOVA) Q4 2019 Earnings Call Transcript
IOVA earnings call for the period ending December 31, 2019.
Iovance Biotherapeutics, Inc. (IOVA) Q3 2019 Earnings Call Transcript
IOVA earnings call for the period ending September 30, 2019.
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.